4D Molecular Therapeutics (NASDAQ:FDMT) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings results on Friday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock traded up $0.05 on Friday, hitting $4.53. The company’s stock had a trading volume of 1,216,782 shares, compared to its average volume of 846,414. The company has a market capitalization of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. 4D Molecular Therapeutics has a 1 year low of $4.20 and a 1 year high of $36.25. The firm has a fifty day moving average price of $5.26 and a 200-day moving average price of $8.71.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Leerink Partners lowered their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Morgan Stanley cut their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. Bank of America cut their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.